14 February 2018 01:30pm - 02:30pm Australia/Sydney
This session will report the results for the TRANSFUSE-RCT, the multi-centre, randomised, controlled trial, testing the effect of the freshest available red blood cell (RBC) unit compared to standard practice, on mortality in critically ill patients who require RBC transfusion.
|Presenter:||Dr Zoe McQuilten, Consultant Haematologist, Senior Research Fellow, Monash University.|
This session will explore both the early treatments for haemophilia and new technologies being implemented and considered to advance treatment.
|Presenter:||Dr Kobie Von Wielligh, Haemostasis Fellow, Central Adelaide Local Health Network|
18 April 2018 01:30 - 02:30pm - Australia/Sydney
Trauma is the leading cause of death worldwide in individual's aged 18-39 with data from the WHO suggesting that worldwide almost 6 million deaths every year are directly attributable to trauma. Despite advances in trauma management, a significant proportion of these deaths are still due to haemorrhage. Death can occur early as a result of uncontrollable haemorrhage; in patients where surgical haemorrhage control is achieved subsequent morbidity and mortality can be attributed to effects of massive haemorrhage and large volume blood product transfusion. This session will provide an update for the Feisty Study - An Australian multi-centre randomised, controlled trial studying the effects of rapid fibrinogen replacement in severely bleeding trauma patients.
|Presenter:||Dr James Winearls, Consultant Intensivist, Gold Coast University Hospital, (Chief Investigator).|
9 May 2018 01:30 - 02:30pm - Australia/Sydney
In good news for Australian Defence Force personnel, and potentially many civilian patients in the future, after five years of intense research and development, results for the Blood Service's Frozen Blood Project are heating up. This exciting work extends the shelf-life of blood components up to 10 years by adapting and developing blood freezing technologies, cryopreservation. Advances it this area are presented.
|Presenter:||Dr Lacey Johnson, Principal Research Fellow, Australian Red Cross Blood Service.|
13 June 2018 01:30 - 02:30pm - Australia/Sydney
The news in "artificial blood” is that two research groups have transformed adult cells into stem cells that can regenerate both themselves and all the cellular components of blood. This development has been described as "the holy grail”, and offers a potential treatment for those who need bone marrow transplants and can't find appropriate donors. This is a significant milestone in regenerative medicine, and if taken to its logical conclusion, may reduce or eliminate the need for bone marrow transplants as well as red cell and platelet donations. However, these reports are a long way (many years) from clinical application in humans at present. The current state of play is presented.
|Presenter:||Dr Rebecca Griffiths, Senior Post Doctoral Scientist - Stem Cell Ageing and Regenerative Engineering Australian Institute for Bioengineering and Nanotechnology, The University of Queensland.|
11 July 2018 01:30 - 02:30pm - Australia/Sydney
Presenter: Dr George Kotsiou, Infectious Disease Specialist, Royal North Shore Hospital.
15 August 2018 01:30 - 02:30pm - Australia/Sydney
Suspected iron deficiency and anaemia remain a problem for pregnant women coming into delivery, and may lead to a red cell transfusion in the event of postpartum haemorrhage (PPH). The Australian Red Cross Blood Service collaborated with health services to conduct clinical practice improvement to support patient blood management initiatives.
|Presenter:||Dr Cindy Flores, Patient Blood Management Education Coordinator, Department of Health and Human Services, Victoria and Australian Red Cross Blood Service.|
12 September 2018 01:30 - 02:30pm - Australia/Sydney
SHOT is the United Kingdom's independent, professionally-led haemovigilance scheme. Since 1996 SHOT has been collecting and analysing anonymised information on adverse events and reactions in blood transfusion from all healthcare organisations that are involved in the transfusion of blood and blood components in the United Kingdom. Where risks and problems are identified, SHOT produces recommendations to improve patient safety.
|Presenter:||Dr Paula Bolton-Maggs, Medical Director, Serious Hazards of Transfusion Scheme NHSBT, UK|
17 October 2018 01:30 - 02:30pm - Australia/Sydney
Direct oral anticoagulants (DOACs) are indicated for the prevention of systemic embolism in selected patients with non-valvular atrial fibrillation and for the prevention and /or treatment of venous thromboembolism. Guidance on when and how to reverse DOACs is discussed.
|Presenter:||Dr Simon McRae, Chairman, Australian Haemophilia Centre Directors Organisation, Consultant Haematologist SA Pathology, Royal Adelaide Hospital.|
14 November 2018 01:30 - 02:30pm - Australia/Sydney
Genomic profiling of red cell and platelet antigens allows for more precise transfusion therapy and is set to change transfusion practice. The impact of genomics on transfusion will be discussed.
|Presenter:||Dr Ben Saxon, National Transfusion Specialist, Australian Red Cross Blood Service, Haematologist, Women's and Children's Hospital, Adelaide.|